# Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform
Canonical URL: https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-publication-in-nature-biotechnology-of-in-vivo-gene-editing-of-human-hematopoietic-stem-cells-in-preclinical-models-using-the-fusogen-platform
Ticker: SANA
Company: Sana Biotechnology
Source: Sana Biotechnology
Published: 2025-12-08 13:59 EST
Original Source URL: https://ir.sana.com
## Summary

Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology  Broadens Application of Fusogen Technology Beyond T Cells to Second Cell Type, HSCs, Showing Potent and Specific in vivo

## Article Body
Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology  Broadens Application of Fusogen Technology Beyond T Cells to Second Cell Type, HSCs, Showing Potent and Specific in vivo
## Recent Company News
- 2026-05-27 20:05 EST — [Sana Biotechnology to Present at June 2026 Investor Conferences](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-june-2026-investor-conferences) — Source: Sana Biotechnology
- 2026-05-15 13:00 EST — [Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility](https://biopharmsignal.com/news/SANA/sana-biotechnology-announces-sale-of-approximately-69-million-of-shares-through-its-at-the-market-atm-facility) — Source: Sana Biotechnology
- 2026-05-12 20:05 EST — [Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs](https://biopharmsignal.com/news/SANA/sana-biotechnology-presents-preclinical-data-for-in-vivo-car-t-cell-therapy-sg293-surrogate-demonstrating-cell-specific-delivery-potent-car-t-cell-generation-and-deep-b-cell-depletion-in-nhps) — Source: Sana Biotechnology
- 2026-05-11 20:05 EST — [Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates](https://biopharmsignal.com/news/SANA/sana-biotechnology-reports-first-quarter-2026-financial-results-and-business-updates) — Source: Sana Biotechnology
- 2026-05-05 20:05 EST — [Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference](https://biopharmsignal.com/news/SANA/sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference) — Source: Sana Biotechnology
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)